Facile synthesis of hyaluronic acid-modified Fe3O4/Au composite nanoparticles for targeted dual mode MR/CT imaging of tumors. Issue 47 (2nd November 2015)

• Record Type: Journal Article
• Authors: Hu, Yong; Yang, Jia; Wei, Ping; Li, Jingchao; Ding, Ling; Zhang, Guixiang; Shi, Xiangyang; Shen, Mingwu
• Is Part Of: Journal of materials chemistry. Volume 3:Issue 47(2015)
• Page Start: 9098
• Page End: 9108
• Publication Date: 2015-11-02
• Subjects: Materials -- Periodicals; Chemistry, Analytic -- Periodicals; Biomedical materials -- Research -- Periodicals; 543.0284
• DOI: 10.1039/c5tb02040a
• Languages: English
• ISSNs: 2050-750X

Abstract

Abstract : Hyaluronic acid-modified Fe3 O4 /Au composite nanoparticles can be synthesized for targeted dual mode MR/CT imaging of tumors. Abstract : A facile co-precipitation approach for synthesizing hyaluronic acid (HA)-modified Fe3 O4 /Au composite nanoparticles (CNPs) for targeted dual mode tumor magnetic resonance (MR) and computed tomography (CT) imaging is reported. In this work, polyethyleneimine (PEI) was employed as a stabilizer to form gold NPs (PEI–Au NPs). In the presence of the PEI–Au NPs, controlled co-precipitation of Fe(ii ) and Fe(iii ) salts was performed, leading to the formation of the Fe3 O4 /Au–PEI CNPs, which were further modified with hyaluronic acid (HA). We show that the formed Fe3 O4 /Au–PEI–HA CNPs are colloidally stable, hemocompatible and cytocompatible in a given concentration range, and have a high affinity to target CD44 receptor-overexpressing cancer cells. Due to the presence of Fe3 O4 and Au components, the formed Fe3 O4 /Au–PEI–HA CNPs display a high r 2 relaxivity (264.16 mM −1 s −1 ) and good X-ray attenuation property, rendering them with an ability to be used as a nanoprobe for targeted dual mode MR/CT imaging of CD44 receptor-overexpressing cancer cells in vitro and a xenografted tumor model in vivo . The Fe3 O4 /Au–PEI–HA CNPs developed via this facile approach may hold great promise to be used as a unique platform for precision imaging of CD44 receptor-overexpressing tumors.